FDA Advisory Committee Recommends Approval of Cologuard
Exact Sciences has announced the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee unanimously voted to approve its stool-based DNA colorectal cancer screening test Cologuard.
In a 90-site trial of the test, Cologuard was found to detect 92.3 percent of colorectal cancer in average risk patients.
The FDA is not obligated to follow the advisory committee's recommendation, but will consider its guidance as Cologuard is evaluated.
More Articles on Gastroenterology:
11 Statistics on Liver Disease & Pancreatitis in the U.S.
18 Statistics on Gastroenterologist Compensation in 2012 vs. 2011
Advocacy in the GI Field: Q&A With AGA President Dr. Anil Rustgi
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
New from Becker's ASC Review